What is the difference between erysipelas and cellulitis in terms of management and treatment?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 11, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Difference Between Erysipelas and Cellulitis

The primary distinction between erysipelas and cellulitis is anatomical depth: erysipelas affects the upper dermis and superficial lymphatics with well-defined borders, while cellulitis involves the deeper dermis and subcutaneous fat with poorly defined borders. 1, 2

Anatomical and Clinical Distinctions

Depth of Infection

  • Erysipelas is limited to the upper dermis, including the superficial lymphatics 1
  • Cellulitis involves the deeper dermis and subcutaneous fat 1

Border Characteristics

  • Erysipelas presents with well-defined, clearly delineated borders of inflammation 1, 2
  • Cellulitis demonstrates poorly defined borders with more diffuse spreading 2

Clinical Presentation Overlap

Both conditions share many clinical features, making them difficult to distinguish in practice 1:

  • Rapidly spreading areas of erythema, swelling, tenderness, and warmth 1
  • Lymphangitis and regional lymph node inflammation 1, 2
  • "Peau d'orange" appearance due to superficial edema around hair follicles 1, 2
  • Vesicles, bullae, petechiae, or ecchymoses may develop 1
  • Systemic manifestations including fever, tachycardia, confusion, hypotension, and leukocytosis 1, 2

Management and Treatment Approach

Diagnostic Workup

For typical cases of either condition, blood cultures, tissue aspirates, or skin biopsies are unnecessary 1, 2. However, consider these investigations for:

  • Patients with malignancy 1, 2
  • Severe systemic features (high fever, hypotension) 1, 2
  • Unusual predisposing factors (immersion injury, animal bites, neutropenia, severe immunodeficiency) 1

Antibiotic Selection

Both erysipelas and cellulitis should be treated with antibiotics active against streptococci, as these are the primary causative organisms 1, 2, 3:

First-Line Oral Options

  • Penicillin 1
  • Amoxicillin 1, 4
  • Amoxicillin-clavulanate 1
  • Dicloxacillin 1
  • Cephalexin 1
  • Clindamycin 1

Penicillin Allergy Alternatives

  • Pristinamycin 4
  • Clindamycin 4

Evidence on Antibiotic Classes

  • Macrolides/streptogramins are more effective than penicillin antibiotics (RR 0.84,95% CI 0.73 to 0.97) 5
  • Oral macrolides can be more effective than intravenous penicillin (RR 0.85,95% CI 0.73 to 0.98) in 3 trials with 419 participants 5
  • No difference between penicillins and cephalosporins (RR 0.99,95% CI 0.68 to 1.43) 5

Treatment Duration

A 5-day course of antimicrobial therapy is as effective as a 10-day course if clinical improvement is seen at 5 days 2. This represents a significant shift from traditional longer courses.

Route of Administration

Most patients can receive oral medications from the start for typical cellulitis/erysipelas 1. Intravenous therapy is reserved for:

  • Signs of severity 4
  • Significant comorbidities (diabetes, arteritis, cirrhosis, immunodeficiency) 4
  • Unfavorable social context 4

Adjunctive Measures

  • Elevation of the affected area accelerates improvement by promoting gravity-driven drainage of edema and inflammatory substances 2
  • Bed rest with leg elevation is important 3
  • Anticoagulants are indicated in patients at risk of venous thromboembolism 3

Prevention of Recurrence

Recurrence is the most distressing complication, affecting approximately 25% of patients within 3 years 6, 7. Prevention strategies include:

Address Predisposing Factors

  • Treat athlete's foot (tinea pedis), which is the most common portal of entry 3
  • Manage venous insufficiency or lymphatic obstruction 1
  • Address skin trauma, ulceration, fissured toe webs, or inflammatory dermatoses 1

Decolonization Regimens

For recurrent cases, consider 2:

  • 5-day decolonization with twice-daily intranasal mupirocin 2
  • Daily bathing with chlorhexidine 2
  • Dilute bleach baths (1/4–1/2 cup per full bath) 2

Long-Term Prophylaxis

  • Prophylactic antibiotic therapy with delayed penicillin is recommended for recurrent erysipelas 4
  • Long-term antibacterial therapy is required for patients with recurrence 3

Common Pitfalls

Terminology Confusion

Physicians use "cellulitis" and "erysipelas" inconsistently 1:

  • Some use "erysipelas" only for facial cellulitis 1
  • In European countries, the terms are often used synonymously 1
  • The distinction based on border definition is the most clinically useful approach 1, 2

Misdiagnosis

Do not label purulent collections as "cellulitis" 1. The term is inappropriate for:

  • Cutaneous abscesses 1
  • Septic bursitis 1
  • Furuncles 1

Primary treatment of true cellulitis/erysipelas is antimicrobial therapy, whereas purulent collections require drainage as the major component of management 1.

Differential Diagnoses to Consider

When presentation is atypical, consider 3, 4:

  • Contact eczema 4
  • Acute arthritis or bursitis 4
  • Chronic dermohypodermitis of venous origin 4
  • Necrotizing fasciitis (if widespread petechiae/ecchymoses with systemic toxicity) 1
  • Neutrophilic dermatoses or eosinophilic cellulitis 4

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Cellulitis Diagnosis and Treatment

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Erysipelas: recognition and management.

American journal of clinical dermatology, 2003

Research

Interventions for cellulitis and erysipelas.

The Cochrane database of systematic reviews, 2010

Research

Cellulitis and erysipelas: prevention.

BMJ clinical evidence, 2015

Research

Cellulitis and erysipelas.

BMJ clinical evidence, 2008

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.